Selpercatinib will expand treatment options available for people with RET fusion positive non small cell lung cancer on the NHS in England.
Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.
The Medicines and Healthcare products Regulatory Agency has approved the first-of-its-kind drug sotorasib for some people with non small cell lung cancer.
A potentially life-extending treatment for some people with non small cell lung cancer (NSCLC) will now be available on the NHS in England.
The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.
The National Institute for Health and Care Excellence has approved the drug osimertinib to treat some adults in England with untreated, advanced lung cancer.
The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland
Adults in England with advanced lung cancer will not have access to a new targeted cancer drug, lorlatinib (Lorviqua).